Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-4007

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-4007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 25mg (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

Losartan Potassium Tab USP 25 mg film-coated tablets packaging label by Preferred Pharmaceuticals Inc. The label states the product is a generic for Cozaar and contains 25 mg of losartan potassium per tablet. Manufacturer is Zhejiang Huahai Pharmaceutical Co., Ltd. The label includes storage instructions, a barcode, and bilingual dosing instructions in English and Spanish.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of losartan potassium showing the molecular arrangement including a chlorinated biphenyl and tetrazole potassium salt groups.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients reaching the primary endpoint over 66 study months between Atenolol and Losartan Potassium. The graph shows Atenolol with a dotted line and Losartan Potassium with a solid line, indicating a 13% adjusted risk reduction for Losartan Potassium (p=0.021). The x-axis represents study months, and the y-axis shows the percentage of patients with the primary endpoint.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months. The graph shows two lines: one for Atenolol (dotted) and one for Losartan Potassium (solid), with Losartan Potassium consistently showing a lower percentage. The graph includes a note on adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol in primary composite outcomes and stroke (fatal/non-fatal). The chart includes event rates, hazard ratios with 95% confidence intervals, and is adjusted for baseline risk factors. The plot displays data segmented by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD).*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over a 48-month period for Losartan Potassium versus placebo. The graph shows two lines: a solid line representing Losartan Potassium and a dashed line representing placebo, with a noted risk reduction of 16.1% and a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.